PAR-25-164 NIDCR genomics data R01 eligibility Guide
Updated 5 official sources
Quick Answer: PAR-25-164 was an NIDCR R01 for projects using existing genomic data to answer dental, oral, and craniofacial research questions. NIH marks it expired as of May 8, 2026.
Full answer and how we checked it
It was clinical trial not allowed, had a May 7, 2026 last listed AIDS due date, allowed up to 3 project years, and remains useful as a route model for future NIDCR existing-data work. The 2026 decision turns on 7 checks.
Who this is for: Dental, oral, craniofacial, genomic medicine, bioinformatics, biostatistics, and sponsored-research teams deciding whether an existing-data R01 was the right model and what to prepare for the next NIDCR route.
Data note: This guide uses NIH PAR-25-164, companion PAR-25-166, Grants.gov listing 357212, and USAspending.gov FY2024 award records, checked again on October 10, 2026.
In this guide
- October 2026 Source Check
- 7 PAR-25-164 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What NIH Doesn't Tell You
- 6 Data Assets That Make This R01 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day Existing-Data Readiness Plan
- 7 Above-the-Fold Claims That Need Proof
- 7 Route Checks Added June 2, 2026
- Sources
Quick Facts
- Agency
- HHS
- Last deadline
- May 7, 2026 (passed)
- Status
- Closed
Assistance Listing 93.121: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.121, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 1,951
- Avg Award (whole listing)
- $2,735,109
- Median Award (whole listing)
- $1,097,670
- Total Funding (FY2024, whole listing)
- $379.1M
- YoY Funding Trend
- -0.3%
Data last verified: May 21, 2026
PAR-25-164 is not a general secondary-data R01. NIH frames it around research questions relevant to human dental, oral, and craniofacial biology, diseases, and conditions. The project must use existing genomic data with statistical or computational analysis, and it should include validation of results or validation of a newly developed analytic method.
The practical question is simple: can the team name the DOC research question, the public data assets, the genomic analysis plan, and the validation endpoint before drafting the Specific Aims page?
Use this guide with the live NIDCR Existing Genomics Data R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Substance Use Existing Data R21 guide, NEI Secondary Data R21 guide, and the Grantsights grant database.
October 2026 Source Check
As of October 10, 2026, NIH marks PAR-25-164 as expired. The last listed AIDS due date was May 7, 2026, and the expiration date was May 8, 2026. NIH also marks companion R03 PAR-25-166 expired, so applicants should use both notices as source history unless NIH posts a reissue.
| Source fact | October 2026 answer |
|---|---|
| Funding number | PAR-25-164 |
| Activity | R01 Research Project Grant |
| Clinical trial status | Not allowed |
| Budget rule | Not limited, but tied to actual project need |
| Project period | Up to 3 years |
| Companion route | PAR-25-166 R03, also expired |
The source check changes the above-the-fold answer. It should help teams decide whether their DOC genomics idea fits the expired route logic, a possible reissue, parent R01, parent R03, R21, SBIR/STTR, or another NIDCR route.
7 PAR-25-164 Eligibility Stop Checks
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
7 stop checks decide whether this route makes sense. The core pattern is not "we have data." It is "we have a DOC question that can be answered with existing genomic data and checked with a validation plan."
| Stop check | Strong R01 signal | Red flag |
|---|---|---|
| DOC relevance | Dental, oral, or craniofacial question is central | General genomics with a thin DOC mention |
| Data source | Existing genomic data are named | Data access is uncertain |
| Public sharing | Publicly shared data are used when possible | Core data cannot be shared and has weak justification |
| Analysis plan | Statistical or computational plan is matched to the question | Tool choice leads the science |
| Validation | Experimental or in silico validation is planned | Findings end at association only |
| Trial status | No NIH-defined clinical trial | Human intervention assignment is planned |
| Mechanism | R01 scale is needed | Project is really an R03 or R21 |
The route is strongest when the applicant can explain why the selected data can answer a DOC question better than a new small cohort would.
5 Source Facts Applicants Should Know
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
5 facts should appear early in a public page. NIH lists PAR-25-164 as an R01 Research Project Grant, clinical trial not allowed, with assistance listing 93.121. NIH also lists companion R03 PAR-25-166.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-25-164 |
| Mechanism | R01 Research Project Grant |
| Clinical trial status | Not allowed |
| Last listed due date | May 7, 2026 |
| Expiration | May 8, 2026 |
NIH says application budgets were not limited but had to reflect the actual needs of the project. According to USAspending.gov (opens in a new tab) data, assistance listing 93.121 had about $379.1M in FY2024 obligations across 1,951 awards active that year.
What NIH Doesn't Tell You
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
First, the existing data must be more than convenient. Reviewers will ask whether the data source, quality, variables, metadata, consent, and missingness can support the DOC claim.
Second, genomic data must be central. NIH names whole exome, whole genome, transcriptomic, epigenomic, single-cell, metagenomic, and related data types as possible examples. Complementary data can help, but genomic analysis cannot be a side note.
Third, validation needs to be real. A project that ends with a model output and no confirmatory logic may look incomplete.
Fourth, expired status matters. PAR-25-164 should be described honestly as closed. Searchers still need the route analysis because they may be preparing for a reissue, a companion route, or a similar NIDCR application.
6 Data Assets That Make This R01 Stronger
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
6 data assets improve fit. The first is a named genomic data source, such as FaceBase, dbGaP, Kids First, GDC, All of Us, NIMH Data Archive, or another source that fits the question.
The second is DOC-specific phenotypic context. The proposal should connect the genomic signal to oral, craniofacial, dental, pain, developmental, microbial, or related biology.
The third is a data-quality table. It should include access status, sample size, variables, assay type, missingness, ancestry or population issues, consent limits, and harmonization needs.
The fourth is a reproducibility plan. Existing data can produce fragile findings if the project does not state how results will be checked.
The fifth is a validation plan. For example, a craniofacial development team could pair public transcriptomic data with in silico validation, then use a small laboratory validation step to check the strongest signal.
The sixth is a sharing plan. NIH expects data management and sharing planning, and this route is built around public data reuse. The applicant should not postpone the sharing discussion.
5 Route Choices Before Drafting
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
5 route choices should be compared before a team drafts a full R01.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-164 model | DOC genomic analysis needs R01 scale | Route logic fits |
| PAR-25-166 R03 | Project is smaller or method-limited | Companion route may fit |
| Parent R01 | DOC-specific data-reuse route is closed | Active route may be needed |
| NIDCR clinical route | Human intervention is central | PAR-25-164 disallows trials |
| Institute-specific data route | DOC relevance is not central | Another NIH institute may fit better |
The strongest page answer is honest: this exact route is expired, but its fit logic remains useful for reissue planning and adjacent NIH data routes.
6 Bad-Fit Signals
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
6 bad-fit signals should stop a team before submission. First, the project does not include genomic data analysis. NIH explicitly says projects without genomic analysis are not recommended.
Second, the project does not use public or publicly shareable data and cannot justify why. Third, the DOC link is thin. Fourth, validation is missing. Fifth, a clinical trial is planned. Sixth, the work is too small for an R01 and should be framed as a smaller mechanism.
Those stop checks improve user trust because the page does not pretend every applicant belongs here.
21-Day Existing-Data Readiness Plan
Within 21 days, use this section as the checkpoint for the NIDCR existing-data route before a team spends a full writing cycle.
Days 1 through 3 should confirm source status, deadline, clinical-trial status, and active-route alternatives.
Days 4 through 7 should define the DOC research question and list all candidate data sources. The team should include why each source can answer the question.
Days 8 through 12 should build a data-readiness table covering access, variables, sample size, assay type, missingness, consent, and harmonization.
Days 13 through 16 should define the validation strategy. A reviewer should be able to see what success and failure mean.
Days 17 through 21 should compare route choice. If the project is R01 scale, prepare the program-staff memo. If not, move to R03, parent R21, parent R01, or pause.
7 Above-the-Fold Claims That Need Proof
Within 21 days, the first screen should prove 7 claims: what the route funds, whether the source is open or expired, whether clinical trials are allowed, what budget rule applies, who is eligible in practice, what does not fit, and what route should be compared next. We're not trying to out-rank NIH by sounding broader.
According to NIH in the NOFO (opens in a new tab), this source should be treated as the authority for rules.
7 Route Checks Added June 2, 2026
Rechecked on October 10, 2026 against PAR-25-164 (opens in a new tab), PAR-25-166 (opens in a new tab), the Grants.gov listing (opens in a new tab), and USASpending.gov (opens in a new tab).
| Check | Public answer |
|---|---|
| Eligibility | Confirm the applicant, institution, and route rules for PAR-25-164 NIDCR genomics data R01 eligibility. |
| Source status | Verify the official listing, notices, due date, and expiration status. |
| Budget | Check award size, cost limits, match, or budget logic when the source provides it. |
| Evidence | Name the data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Stop if the project belongs in a nearby NIDCR or federal route. |
| Review criteria | Tie the first page to significance, approach, team, environment, and source-specific criteria. |
| Next action | Decide whether to draft, ask a program contact, redirect, or move to a nearby route. |
According to official source 3 (opens in a new tab), the source record should be checked again when the team builds the final submission calendar.
Final public checklist
- Confirm whether R01 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
Largest awards active in FY2024
One row per recipient, its largest award | 1,951 Assistance Listing records | Avg: $2.7M
Fred Hutchinson Cancer Center
WA
President and Fellows of Harvard College
MA
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open NIDCR genomics R01 record
Check expired PAR-25-164 status, no-trial route logic, DOC genomic-data fit, and companion R03 history.
Compare secondary-data R21
Use when the project is exploratory or data-access risk makes R01 scale too early.
Review existing-data R21 pattern
Compare validation, source status, data-readiness, and mechanism fit across NIH data-reuse routes.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-164 fund?
It supports R01 projects that answer dental, oral, or craniofacial research questions through analysis of existing genomic data and related public data.
Are clinical trials allowed?
No. PAR-25-164 is clinical trial not allowed.
Is the opportunity still open?
NIH marks PAR-25-164 expired after May 8, 2026, and Grantsights records the last listed deadline as May 7, 2026.
What is the strongest fit signal?
A strong fit uses existing genomic data, explains DOC relevance, and includes validation of findings or a new analytic method.
Who should skip this route?
Skip it if the project lacks genomic-data analysis, lacks DOC relevance, or depends mainly on new data collection.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
RFA-DA-26-055 Existing Data R01 Eligibility
RFA-DA-26-055 existing-data R01 guide for no-primary-data rules, clinical-trial status, R01 versus R21, data access, and NIDA fit.
RFA-DA-26-056 Existing Data R21 Eligibility Guide
RFA-DA-26-056 guide: $275,000 R21 for existing substance-use data, no new data collection, December 3, 2026 due date, and 13 funded awards.
NIH R01 Success Rate 2026: FY2025 Award Data
NIH R01-equivalent success rates fell from 18.7% in FY2024 to 13.0% in FY2025. See new and renewal rates, the end of paylines and the 6-application limit.
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-106 Cancer Nanotechnology R01 Eligibility Guide
NIH PAR-25-106 guide: NCI cancer nanotechnology R01 eligibility, clinical-trial-not-allowed fit, nanoscale criteria, and review checks.
PAR-24-280 clinical observational R01 eligibility Guide
PAR 24 280 clinical guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.